Venetoclax
Back to searchMolecule Structure
Scientific Name
Venetoclax
Description of the Drug
Venetoclax is a BCL-2 inhibitor used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, or acute myeloid leukemia.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11581
http://www.drugbank.ca/drugs/DB11581
Brand Name(s)
Venclexta
Company Owner(s)
Abbvie Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Apoptosis regulator Bcl-2 | SINGLE PROTEIN | INHIBITOR | CHEMBL4860 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL523816 | |
PharmGKB | PA166153473 | |
Human Metabolome Database | HMDB0247760 | |
DrugBank | DB11581 | |
PubChem: Thomson Pharma | 104174762 | |
PubChem | 49846579 | |
LINCS | LSM-45468 | |
PDBe | LBM | |
BindingDB | 60828 | 50162774 |
EPA CompTox Dashboard | DTXSID30154863 | |
DrugCentral | 5133 | |
ChemicalBook | CB73339265 | CB62645962 |
Guide to Pharmacology | 8318 | |
rxnorm | VENETOCLAX | VENCLEXTA |
ChEBI | 133021 | |
ZINC | ZINC000150338755 |